OxSonics Therapeutics

OxSonics was established to develop and commercialise a new generation of ultrasound-based medical devices. Its drug delivery platform, SonoTran has the capability to overcome one of the greatest limitations facing solid tumour cancer therapy: delivering drugs throughout tumour volumes including to those areas that lie farthest from blood vessels. SonoTran can be applied to any oncological drug class. In addition, it provides on-screen feedback as to where and when drug delivery has taken place, maximizing the potential of complete tumour coverage. These features combined have the potential to maximise the therapeutic potential of a broad range of solid tumour cancer drugs. OxSonics mission is to provide economic and scalable life-changing treatments to solid tumour cancer patients. OxSonics is based in Oxford, UK.